Committee Action
116TH CONGRESS Subcommittee Hearing on Examining Surprise Billing: Protecting Patients from Financial Pain On April 2, 2019, the Subcommittee on Health, Employment, Labor, and Pensions (HELP) held a hearing entitled ``Examining Surprise Billing: Protecting Patients from Financial Pain,'' which discussed hospital billing practices, including unexpected costs to consumers due, in part, to a lack of transparency in health care. The witnesses were Ms. Ilyse Schuman, Senior Vice President, Health Policy, American Benefits Council, Washington, D.C.; Dr. Jack Hoadley, Research Professor Emeritus, Health Policy Institute, Georgetown University McCourt School of Public Policy, McLean, Virginia; Mr. Frederick Isasi, Executive Director, Families USA, Washington, D.C.; and Ms. Christen Linke Young, Fellow, USC Brookings Schaeffer Initiative on Health Policy, Washington, D.C. Members and witnesses discussed the need for more transparency in hospital billing. Witnesses further discussed the positive impact that increased transparency will have on boosting competition in health care. Subcommittee Hearing on Making Health Care More Affordable: Lowering Drug Prices and Increasing Transparency On September 26, 2019, the HELP Subcommittee held a hearing entitled ``Making Health Care More Affordable: Lowering Drug Prices and Increasing Transparency,'' which examined the impact of rising prescription drug prices on workers and businesses, and the need for greater transparency. Members and witnesses discussed how information on PBMs' price negotiations with drug manufacturers is not provided to consumers. The witnesses were Mr. Frederick Isasi, Executive Director, Families USA, Washington, D.C.; Mr. David Mitchell, Founder, Patients for Affordable Drugs, Washington, D.C.; Ms. Bari Talente, Executive Vice President, National Multiple Sclerosis Society, Washington, D.C.; Dr. Mariana Socal, Assistant Scientist, Johns Hopkins University Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, Maryland; Mr. Christopher Holt, Director of Health Care Policy, American Action Forum, Washington, D.C.; and Dr. Craig Garthwaite, Associate Professor of Strategy, Northwestern University Kellogg School of Management, Evanston, Illinois. Full Committee Markup of H.R. 5800, the Ban Surprise Billing Act On February 11, 2020, the Committee met to mark up H.R. 5800, the Ban Surprise Billing Act. The legislation included provisions improving transparency with respect to group health plan service providers, including those providing brokerage and consulting services. The Committee favorably reported the bill, as amended, by a vote of 32 yeas and 13 nays. 117TH CONGRESS Subcommittee Hearing on Lower Drug Costs Now: Expanding Access to Affordable Health Care On May 5, 2021, the HELP Subcommittee held a hearing entitled ``Lower Drug Costs Now: Expanding Access to Affordable Health Care.'' The witnesses were Dr. Douglas Holtz-Eakin, President, American Action Forum, Washington, D.C.; Mr. Frederick Isasi, Executive Director, Families USA, Washington, D.C.; Mr. David Mitchell, Founder, Patients for Affordable Drugs, Washington, D.C.; and Dr. Mariana Socal, Assistant Scientist, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. The hearing included a discussion regarding how the lack of PBM transparency contributes to higher costs for plans and consumers. Full Committee Hearing Examining the President's Fiscal Year 2023 Budget Proposal for the Department of Health and Human Services On April 6, 2022, the Committee held a hearing entitled ``Examining the Policies and Priorities of the U.S. Department of Health and Human Services.'' The sole witness was the Honorable Xavier Becerra, Secretary of the U.S. Department of Health and Human Services (HHS), Washington, D.C. The lack of transparency in PBMs' activities and the impacts on health plans was discussed at the hearing. 118TH CONGRESS Subcommittee Hearing on Reducing Health Care Costs for Working Americans and Their Families On April 26, 2023, the HELP Subcommittee held a hearing entitled ``Reducing Health Care Costs for Working Americans and Their Families,'' which examined the need for increased transparency in health care and lowering costs by expanding oversight into PBMs. During the hearing, members and witnesses discussed how a lack of transparency is associated with PBMs not passing on savings to employer-provided health plans. The witnesses were Mr. Joel White, President, Council for Affordable Health Coverage, Washington, D.C.; Mrs. Tracy Watts, Senior Partner, Mercer, Washington, D.C.; Ms. Marcie Strouse, Partner, Capitol Benefits Group, Des Moines, Iowa; and Ms. Sabrina Corlette, J.D., Research Professor and Co-Director, Center on Health Insurance Reforms, Georgetown University's McCourt School of Public Policy, Washington, D.C. Full Committee Hearing Examining the President's Fiscal Year 2024 Budget Proposal for the Department of Health and Human Services On June 13, 2023, the Committee held a hearing entitled ``Examining the Policies and Priorities of the U.S. Department of Health and Human Services.'' The sole witness was the Honorable Xavier Becerra, Secretary of HHS, Washington, D.C. Secretary Becerra spoke to the need for improved transparency of PBMs' activities. Subcommittee Hearing on Competition and Transparency: The Pathway Forward for a Stronger Health Care Market On June 21, 2023, the HELP Subcommittee held a hearing entitled ``Competition and Transparency: The Pathway Forward for a Stronger Health Care Market,'' which examined the need to improve competition and transparency in health care. The witnesses were Dr. Gloria Sachdev, President and CEO, Employers' Forum of Indiana, Carmel, Indiana; Ms. Sophia Tripoli, Senior Director of Health Policy and Director of the Center for Affordable Whole-Person Care, Families USA, Washington, D.C.; Mr. Greg Baker, CEO, AffirmedRx, Louisville, Kentucky; Ms. Christine Monahan, Assistant Research Professor, Center on Health Insurance Reforms, Georgetown University Center McCourt School of Public Policy, Washington, D.C.; and Mr. Juan Carlos ``JC'' Scott, President and CEO, Pharmaceutical Care Management Association, Washington, D.C. Full Committee Markup of H.R. 4507, the Transparency in Coverage Act On July 10, 2023, Rep. Bob Good (R-VA-5), Chairman of the HELP Subcommittee, introduced H.R. 4507, the Transparency in Coverage Act, with Rep. Mark DeSaulnier (D-CA-10), Ranking Member of the HELP Subcommittee, as an original cosponsor. On July 12, 2023, the Committee met to mark up H.R. 4507 and The Committee adopted an Amendment in the Nature of a Substitute offered by Rep. Good, which made technical changes to H.R. 4507. Rep. Lori Chavez-DeRemer (R-OR-5) offered an amendment to add the Safe Step Act (H.R. 2630, 118th), legislation requiring group health plans to offer exceptions to step-therapy protocols, to the bill. The amendment was withdrawn. The Committee reported the bill favorably, as amended, to the House of Representatives by a vote of 38 yeas and 1 nay. Committee Views TRANSPARENCY IN COVERAGE In 2020, the U.S. Departments of Labor, HHS, and the Treasury (jointly tri-agencies) published a final rule titled ``Transparency in Coverage''\3\ (TiC) requiring that most health plans and issuers make available to participants and beneficiaries personalized, out-of-pocket cost information and the underlying negotiated rates for all covered health care items and services (including prescription drugs) through an internet-based self-service tool and in paper form upon request. The rule also requires that most health plans and issuers make available to the public three separate machine- readable files that include detailed pricing information. --------------------------------------------------------------------------- \3\Transparency in Coverage, 85 Fed. Reg. 72,158 (Nov. 12, 2020). --------------------------------------------------------------------------- While parts of the TiC rule were slated to go into effect on January 1, 2022, the tri-agencies delayed some implementation deadlines by six months.\4\ On July 1, 2022, the Centers for Medicare and Medicaid Services (CMS) within HHS began enforcing the requirement that health plans publicly disclose the contracted prices they pay their in-network health care providers and the allowed amounts they will pay out-of- network providers. Beginning January 1, 2023, health plans were required to create a tool for their enrollees to receive real- time, personalized estimates of potential cost-sharing liability for 500 designated items and services. As of January 1, 2024, the cost-sharing tool must provide the same information for all covered items and services.\5\ Noncompliant payers may face fines of up to $100 per day for each violation and for each individual affected. --------------------------------------------------------------------------- \4\https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our- activities/resource-center/faqs/aca-part-49.pdf. \5\Id. --------------------------------------------------------------------------- In August 2021, the U.S. Chamber of Commerce and the Pharmaceutical Care Management Association (PCMA) filed lawsuits challenging the requirement that PBMs must report the historical net price of prescription drugs. The lawsuits argued that federal officials could not require the disclosure of historical net price information.\6\ These organizations withdrew their lawsuits after the tri-agencies issued guidance deferring enforcement of the drug-price transparency provisions pending further rulemaking.\7\ --------------------------------------------------------------------------- \6\https://www.healthaffairs.org/content/forefront/two-new- lawsuits-challenge-insurer-transparency-rule. \7\https://news.bloomberglaw.com/health-law-and-business/end-delay- of-drug-price-transparency-rule-employer-group-urges. --------------------------------------------------------------------------- Experts have identified ways to build on the TiC rule to make data more accessible and user-friendly and to improve compliance. A recent report found that many of the uploaded data files are too large to access and the data as presented is challenging to understand.\8\ The TiC rule preamble discusses the benefits of standardizing the data for the use of standards-based application programming interface (API) to improve access and plan compliance. Access to pricing information through an API could have a number of benefits for consumers, employers, and providers, including providing real- time access to pricing information, providing access to personalized actionable health care price estimates through an application of the consumer's choice, and enabling third-party developers to develop internet-based self-service tools.\9\ --------------------------------------------------------------------------- \8\https://georgetown.app.box.com/s/ 1ezsggz1c7smsaexkr8rght15sokgusl. \9\Transparency in Coverage, 85 Fed. Reg. 72,158 (Nov. 12, 2020). --------------------------------------------------------------------------- TiC reporting requirements are geared towards fee-for- service reporting and fail to capture prices fully from value- based arrangements (VBAs). The Transparency in Coverage Act addresses this shortcoming. PHARMACY BENEFIT MANAGER REPORTING PBMs serve as intermediaries between pharmaceutical manufacturers and health insurers, Medicare Part D drug plans, employers, and other payers. PBMs create formularies, negotiate rebates with manufacturers, process claims, create pharmacy networks, and review drug utilization. The Congressional Budget Office (CBO) found that PBMs' ability to negotiate larger rebates from manufacturers has helped lower governmental costs and copays for plan enrollees.\10\ However, in light of rising health care costs, PBMs have faced growing scrutiny for their role in prescription drug costs and spending. --------------------------------------------------------------------------- \10\https://www.cbo.gov/system/files/2019-05/55151- SupplementalMaterial.pdf. --------------------------------------------------------------------------- By negotiating with drug manufacturers and pharmacies to control costs, PBMs have a significant behind-the-scenes impact in determining total drug costs for insurers, shaping patients' access to medications, and determining how much pharmacies are paid. PBMs primarily earn profits through administrative fees charged for their services, spread pricing, and shared savings, where the PBM keeps part of the rebates or discounts negotiated with drug manufacturers. There has been increasing concern that the current structure creates a perverse incentive as higher list prices for drugs often translate into higher compensation for PBMs. Policymakers have also raised concerns that patients lack adequate line of sight into the financial flows and incentives that inform pricing.\11\ --------------------------------------------------------------------------- \11\https://oversight.house.gov/wp-content/uploads/2021/12/PBM- Report-12102021.pdf. --------------------------------------------------------------------------- Three PBMs--CVS Caremark, Express Scripts, and OptumRx-- account for nearly 90 percent of the market.\12\ While some have argued that this consolidation increases the bargaining power of PBMs relative to drug manufacturers, others have raised concerns that less competition among PBMs reduces competitive pressures and may allow them to earn higher profits than they would in a more competitive market. --------------------------------------------------------------------------- \12\https://content.naic.org/cipr-topics/pharmacy-benefit-managers. --------------------------------------------------------------------------- PBMs have also come under scrutiny for vertically integrating with health insurers and pharmacies. The three largest PBMs are each vertically integrated with a major health insurer--CVS Caremark with Aetna, Express Scripts with Cigna, and OptumRx with UnitedHealth Group. In its 2023 Report to Congress, the Medicare Payment Advisory Committee (MedPAC) warns that these large PBMs may have conflicting interests among their integrated entities.\13\ The Federal Trade Commission is currently studying the effects of vertical integration on access to prescription drugs.\14\ --------------------------------------------------------------------------- \13\https://www.medpac.gov/wp-content/uploads/2023/03/ Mar23_MedPAC_Report_To_ Congress_SEC.pdf. \14\https://www.ftc.gov/news-events/news/press-releases/2022/06/ ftc-launches-inquiry-prescription-drug-middlemen-industry. --------------------------------------------------------------------------- PBM reimbursement methods can be complex and unclear. Two practices of particular concern are rebate pricing models and spread pricing. For certain prescriptions, PBMs receive rebates and discounts from pharmaceutical companies in exchange for formulary placement. One study found a direct correlation between rebate increases and manufacturer price increases: a $1 increase in rebates corresponds with a $1.17 increase in drug list price, suggesting that rebates play a role in increasing list prices.\15\ PBMs may retain manufacturer rebates as profits rather than passing them through to their health plan clients. When health plans lack full transparency and cannot see how much manufacturers paid in rebates, they do not know how much their PBM retained as profits. --------------------------------------------------------------------------- \15\https://healthpolicy.usc.edu/research/the-association-between- drug-rebates-and-list-prices/. --------------------------------------------------------------------------- Spread pricing occurs when PBMs charge health plans and payers more for a prescription drug than what they reimburse to the pharmacy and then keep the difference. Because neither the plan nor the pharmacy knows what the other side was paid or charged, the practice hides the PBM's margins. State auditors have found PBMs overcharging Medicaid programs by more than $415 million in Ohio, Kentucky, Illinois, and Arkansas. Allegations of overcharging were settled in Kansas for $27.6 million, New Hampshire for $21.2 million, and New Mexico for $13.7 million.\16\ --------------------------------------------------------------------------- \16\https://oversight.house.gov/wp-content/uploads/2023/03/Letter- to-CMS.pdf. --------------------------------------------------------------------------- In the 116th Congress, S. 1895, the Lower Health Care Costs Act of 2019, was a bipartisan bill reported by the Senate Committee on Health, Education, Labor, and Pensions. It would have required PBMs to provide quarterly reports to plan sponsors with detailed data on prescription drug spending, including the acquisition cost of drugs, total out-of-pocket spending, a formulary placement rationale, and aggregate rebate information. CBO estimated that subsequent iterations of this legislation would save the federal government $2.2 billion over the 10-year budgetary window.\17\ --------------------------------------------------------------------------- \17\https://www.cbo.gov/system/files/2022-06/hr7666.pdf. --------------------------------------------------------------------------- During the HELP Subcommittee's June 21, 2023, hearing on ``Competition and Transparency: The Pathway Forward for a Stronger Health Care Market,'' Ms. Monahan spoke in support of codifying the Transparency in Coverage rule.\18\ Mr. Baker, Ms. Monahan, Ms. Tripoli, and Dr. Sachdev each expressed support for increased PBM transparency.\19\ --------------------------------------------------------------------------- \18\https://www.congress.gov/118/meeting/house/116125/witnesses/ HHRG-118-ED02-Wstate-MonahanC-20230621.pdf. \19\https://www.congress.gov/118/meeting/house/116125/witnesses/ HHRG-118-ED02-Wstate-MonahanC-20230621.pdf; https://www.congress.gov/ 118/meeting/house/116125/witnesses/HHRG-118-ED02-Wstate-SachdevG- 20230621.pdf; https://www.congress.gov/118/meeting/house/116125/ witnesses/HHRG-118-ED02-Wstate-BakerG-20230621.pdf; https:// www.congress.gov/118/meeting/house/116125/witnesses/HHRG-118-ED02- Wstate-TripoliS-20230621.pdf. --------------------------------------------------------------------------- H.R. 4507, Transparency in Coverage Act H.R. 4507, the Transparency in Coverage Act, amends ERISA, the Public Health Service Act (PHSA), and the Internal Revenue Code (IRC) to promote price transparency in group health plans and health insurance coverage. The bill codifies the tri-agency TiC rule, which increased requirements on plans to make pricing data public and provide information directly to participants and beneficiaries. The bill also prevents group health plans from contracting with PBMs unless PBMs report certain payment information to plan administrators.\20\ --------------------------------------------------------------------------- \20\H.R. 4507 allows for the submission of certain information in lieu of a dollar amount in limited circumstances. T